More Capital or New Leadership? A VC Board Framework for a Company Missing Its Milestones
A missed milestone should trigger re-underwriting, not reflexive blame. The board has to decide whether the investment still deserves more capital and whether the incumbent team is still the best team to deploy it.
Gaurav Shah | Managing Partner, Arete Ventures
A venture-backed company misses its revenue plan. Cash runway is shortening. The CEO argues that the market opportunity remains intact and another financing tranche will buy the time needed to prove it. One director believes the go-to-market plan was wrong. Another thinks the company has outgrown the founder. A third is reluctant to replace management in the middle of a difficult funding environment.
At first glance, this looks like a capital decision or a CEO decision. In practice, the board is underwriting two things at the same time: whether the investment thesis still deserves support and whether the current leadership team remains the best team to convert that support into value.
Those decisions are related, but they are not the same. A strong management team can be executing against assumptions that are no longer true. A valid investment thesis can be trapped behind weak execution. A capable founder can be working inside a governance model that has become contradictory. A board can also spend months debating management when the real problem is that product-market fit was never as established as the last financing round implied.
This is why a missed milestone should not be translated directly into a leadership verdict. It should trigger a re-underwriting of the investment. Leadership is one variable in that re-underwriting.
A missed milestone is not evidence that the CEO should be replaced. It is evidence that the investment needs to be re-underwritten. Leadership is one variable in that re-underwriting.
A Missed Milestone Is a Symptom, Not a Diagnosis
Venture boards operate with incomplete information. Plans are built around assumptions about customer adoption, sales productivity, hiring velocity, product delivery, pricing, competitive response and the timing of the next financing. Some of those assumptions will be wrong even when management is competent.
The board's first job is therefore attribution. What exactly missed plan, why did it miss, and which part of the original underwriting should now be changed? The answer matters because the interventions are economically different. Funding a strategy problem gives the company more time to pursue the wrong plan. Replacing a CEO for an underwriting error destroys continuity without repairing the thesis. Keeping a weak leadership team because the market is difficult converts a management problem into a financing problem.
The cleanest starting question is simple: what changed since the last financing round? If the company is being judged against assumptions that no longer describe the market, capital environment or product maturity, the board needs to separate management variance from underwriting variance before deciding who is accountable.
The Board and Lead Investors Need Two Separate Judgments: The Thesis and the Team
A useful way to force clarity is to evaluate confidence in the investment thesis separately from confidence in the leadership team. The matrix does not make the decision for the board. It prevents two distinct judgments from collapsing into one.
Investor / board diagnosis | Implication |
|---|---|
HIGH confidence in thesis / HIGH confidence in leadership | Continue funding selectively if the economics justify it. Reset milestones only where the underlying evidence supports the reset. Hold management accountable for the revised plan. |
HIGH confidence in thesis / LOW confidence in leadership | The asset may deserve additional support, but capital should be linked to a leadership intervention. Consider augmentation, succession or a staged transition before another large financing simply extends the same execution pattern. |
LOW confidence in thesis / HIGH confidence in leadership | Re-underwrite, pivot or narrow the strategy before committing substantial new capital. A strong CEO should not be asked to defend assumptions the board no longer believes. |
LOW confidence in thesis / LOW confidence in leadership | Avoid solving two broken variables with another financing round. Consider strategic alternatives, controlled restructuring, leadership stabilization only where it protects value, or a decision not to continue funding. |
The uncomfortable quadrant is low confidence in both. Boards sometimes reach for a new CEO because leadership change feels actionable while thesis impairment is harder to admit. But replacing management in a weak investment thesis can put a better executive in charge of destroying the remaining capital more efficiently.
The reverse is equally costly. Continuing to fund a sound thesis through a leadership team that repeatedly cannot execute turns a solvable management problem into a runway problem.
Before Changing the CEO, Determine What Actually Failed
1. Did the Investment Thesis Fail?
The most important question is whether the economic reason for owning the company still holds. Has customer willingness to pay changed? Has the competitive structure shifted? Are unit economics structurally worse than assumed? Is the addressable market smaller or slower to develop? Was product-market fit treated as proven when the evidence was still narrow?
A leadership change can improve execution, but it cannot manufacture a market that does not exist. If the board no longer believes the core thesis, the decision should move upstream to strategy, capital preservation and alternatives. Searching for a new CEO before answering that question can create false precision around the wrong problem.
What not to do: use a CEO search to postpone recognition that the investment case itself has weakened.
2. Did the Operating Plan Fail?
The thesis can be sound while the plan is not. A company may have hired ahead of repeatable demand, expanded internationally before the core motion was stable, built a sales capacity model around productivity that never materialized, or funded a product roadmap that fragmented engineering attention. These are operating-plan errors, and the board has to understand who authored the assumptions and what evidence existed when they were approved.
This distinction matters because management can execute a bad plan faithfully. If the board and investors encouraged growth, hiring or geographic expansion that the evidence did not support, it is too convenient to convert the resulting burn into a pure CEO-performance issue.
What not to do: hold management solely accountable for a plan the board helped create without first resetting the operating assumptions.
3. Did Execution Fail?
Execution failure begins when the plan remains credible but management repeatedly fails to translate it into decisions and operating results. The evidence is rarely one missed quarter. It is a pattern: forecasts stay optimistic after contrary evidence appears, corrective action arrives late, functional leaders remain in role despite repeated gaps, priorities change without resource reallocation, and board decisions do not become operating cadence.
The key test is not whether the CEO can explain the miss. It is whether the organization learns fast enough to change the next outcome. In venture companies, where strategy and operating conditions evolve quickly, the ability to update is part of execution.
What not to do: give another round of capital merely because the company can produce a plausible narrative for each individual miss.
4. Has Leadership Become the Constraint?
Leadership becomes the investment constraint when the company needs a different level or type of judgment faster than the incumbent team can credibly build it. The question is broader than whether the founder has scaled before.
A board should look for evidence that the CEO recognizes bad news before it becomes unavoidable, reallocates resources when facts change, upgrades leaders before functional weakness becomes enterprise risk, attracts executives who are stronger in areas the CEO does not own, and can preserve trust while making difficult trade-offs. The strongest signal is often the quality of decisions under pressure, not the pedigree accumulated before joining the company.
A founder can remain the right strategic leader while needing a President, COO, CFO or CRO. An external CEO can also fail if the actual constraint is product, governance or financing. The title of the intervention should follow the diagnosis.
What not to do: search for a generically 'more experienced' CEO without specifying which decisions the current leader can no longer make at the required level.
5. Has Governance Become the Constraint?
Some apparent management problems are board problems. Different investors may be pushing growth, efficiency and strategic optionality at the same time. Directors may intervene deeply in hiring and pricing, then hold the CEO accountable for results as though decision rights were unchanged. The board may keep resetting milestones without agreeing what would cause it to stop funding. Or it may delay a leadership decision because the founder relationship is politically difficult.
A CEO cannot be fully accountable for outcomes without enough authority to run the company. A board also cannot expect management to optimize simultaneously for mutually incompatible objectives. When governance is the problem, adding another executive can increase organizational complexity without restoring decision clarity.
What not to do: recruit a new CEO into the same governance system that made the incumbent role unworkable.
Runway Changes the Decision
The same diagnosis can produce a different intervention depending on how much time and cash remain. Leadership change has an economic duration: search, candidate notice, closing, onboarding, team assessment, organizational reset and the time required for the new leader to produce evidence. A board can identify the correct leadership change too late for the company to finance the transition.
This is why runway should be treated as a constraint on the decision, not as the diagnosis itself. Short runway does not prove that management failed. It changes which remedies remain available.
Runway condition | Board implication |
|---|---|
Runway supports an orderly reset | Board can compare augmentation, CEO succession and operating-plan reset without compressing assessment. The priority is accuracy of diagnosis and role design. |
Runway is becoming restrictive | Sequence matters. Decide which leadership or operating changes must occur before the next financing, which can happen after it, and what investors need to see to support additional capital. |
Runway is critically short | A full search may not solve the immediate problem. Stabilization, interim leadership, cost reset, financing, asset sale or wind-down alternatives may have to be evaluated alongside permanent succession. |
Boards often ask whether the company should hire before or after the next round. That framing is incomplete. The better question is whether the leadership intervention can create credible evidence soon enough to improve the probability, terms or strategic logic of the next financing.
Replacement Is Only One of Four Board Interventions
Continue With the Current Team
If the thesis remains attractive, the operating plan has been credibly reset and management is learning quickly, continuity may be more valuable than disruption. The board should make the revised milestones explicit, identify the assumptions that matter most and define what evidence would change its confidence. Continuing with the team should be an affirmative underwriting decision, not the absence of a decision.
Augment the Team
Many venture leadership problems are functional before they are CEO-level. A founder may need a President who can build operating cadence, a CFO who can tighten planning and capital discipline, a CRO who can establish repeatable go-to-market, or an independent director who can add pattern recognition without displacing management.
Augmentation works only if decision rights are clear. Hiring around a leader without changing how decisions are made can create a senior team with overlapping mandates and unresolved authority.
Related perspective: Replace the Founder-CEO, Hire a President/COO, or Fix the Governance Model?"
Change Leadership
A CEO transition becomes appropriate when the company still has an investable path, but the board no longer has credible evidence that the incumbent can deliver the next required outcomes within the available time and capital. At that point, delay has a compounding cost. Management teams lose confidence, strong executives leave, financing conversations become harder and the successor inherits less runway.
The board should still separate the need for change from the profile of the successor. The fact that the current CEO is no longer right does not tell you whether the next leader should be a scale operator, a turnaround executive, a product-led CEO, a commercial builder or an interim stabilizer.
Re-underwrite, Pivot or Stop Funding
Sometimes the highest-quality board decision is that no executive change makes the investment sufficiently attractive. The company may need to narrow the product, pursue a strategic transaction, reset the cost base, sell assets or stop consuming capital. This is not a failure of executive search. It is an investment conclusion.
A credible search adviser should be comfortable with that conclusion. The strongest search mandate begins when the board has already decided that leadership is a variable worth changing.
Evidence That Leadership Has Become an Investment Requirement
When leadership is the suspected constraint, the board should test evidence rather than rely on generalized concerns about 'scale' or 'fit.' Six dimensions are particularly revealing.
Assessment dimension | What the board should test |
|---|---|
Forecast integrity | Does management expose downside assumptions early, distinguish signal from hope and explain what changed without rewriting the prior record? |
Learning velocity | How quickly does new evidence change the operating plan, resource allocation and executive priorities? |
Resource allocation | Does capital follow current evidence, or do sunk-cost commitments continue because they are politically difficult to reverse? |
Talent density | Does the CEO recruit, retain and upgrade executives capable of owning the next stage, including people stronger than the CEO in critical functions? |
Operating cadence | Do strategic priorities become accountable decisions, metrics, owners and follow-through across the organization? |
Institutional confidence | Do the board, senior team, key customers and financing counterparties still trust management's judgment when the news is bad? |
These tests are more useful than asking whether someone has 'done Series C before.' Prior stage experience can help, but stage labels are weak proxies for the decisions a specific company now needs.
The Board Decision Memo: Before Approving More Capital or Changing Leadership
Before another material financing is approved or CEO succession is initiated, the decision should be summarized on one page. The purpose is not bureaucracy. It is to stop investors and directors from solving different problems under the same agenda item.
Board question | Why it belongs in the memo |
|---|---|
1. What specifically missed plan? | Name the operating or financing outcome. Avoid broad statements such as 'growth is weak' or 'execution is off.' |
2. What is the current diagnosis? | Thesis, operating plan, execution, leadership, governance, or a combination. State the evidence and the unresolved uncertainty. |
3. What changed since the last financing? | Separate external or underwriting changes from management variance. |
4. How much time remains to correct it? | Map runway against the time needed for the proposed intervention to produce evidence. |
5. Which intervention has the highest probability-adjusted return?
| More capital, plan reset, executive augmentation, CEO change, strategic transaction or stop-funding decision. |
6. What must be demonstrably different in the next 6 to 12 months? | Define the evidence that would validate the intervention and the conditions that would trigger another decision. |
The board should not ask, 'Do we still believe in the CEO?' before it can answer, 'What problem are we asking the CEO to solve, and do we still believe the investment deserves the capital required to solve it?'
Underwrite the Leadership Change Before Writing the Job Specification
Once the diagnosis points to a genuine leadership constraint, the board should resist the instinct to begin with a familiar role description. A generic specification usually imports the résumé of the last successful executive the directors remember. The mandate should instead be built backward from the investment problem.
Question before search | Why it matters |
|---|---|
What specifically has changed? | Clarifies why the incumbent model no longer fits and prevents a search for a generic 'better CEO.' |
What must the new leader accomplish?
| Translates the investment case into operating outcomes rather than background requirements. |
What should be preserved from the founder or current team? | Protects product insight, customer relationships, culture, technical authority or other company-specific advantage. |
What authority will the successor actually have? | Prevents recruiting into a governance structure where accountability and decision rights are misaligned. |
What runway exists for transition? | Shapes whether the mandate should be permanent, interim, staged or paired with immediate stabilization. |
The CEO specification should be the output of the investment diagnosis, not the starting point of the search. The same principle applies to a President, COO, CFO, CRO or independent director. The title is useful only after the board knows which constraint it is trying to remove.
Leadership Is a Capital Allocation Decision
In a venture-backed company, leadership and capital cannot be evaluated independently for long. The CEO determines how cash becomes product, customers, talent and operating evidence. Lead investors decide whether to commit additional capital; the board governs how the company uses that capital and whether the leadership model remains fit for the plan.
A weak diagnosis produces expensive false choices. More capital can mask leadership failure. Leadership change can mask thesis failure. Board intervention can mask governance failure. The discipline is to identify which variable is impaired before consuming more of the two resources venture companies cannot recover easily: time and cash.
The highest-quality decision is therefore not always to fund or to replace. It is to know why one of those actions changes the probability of reaching the next value-creating milestone, and why the alternatives do not.